In support of improving IBD diagnosis and treatment, LabCorp has launched an expanded IBD testing profile that helps to identify IBD patients and differentiate between ulcerative colitis and Crohn’s disease. The IBD Expanded Profile includes ulcerative colitis and Crohn’s disease-specific antibody markers that improve diagnostic sensitivity and provide valuable prognostic information regarding the severity of disease. For patients diagnosed with IBD, LabCorp’s TPMT Enzyme Activity assay can be utilized prior to thiopurine drug treatment to assess dosing levels and potential adverse drug reaction. Once a patient has started thiopurine treatment, physicians can use the thiopurine Metabolites test to help optimize ongoing dosing to reach and maintain therapeutic goals and avoid possible drug toxicity. LabCorp also offers testing for patients treated with new biological drugs like infliximab that allow physicians to monitor drug concentration levels and assess the impact of anti-infliximab antibody levels on drug efficacy.